Aikium

Aikium Inc., founded in 2022 and headquartered in Berkeley, California, is a biotechnology startup specializing in protein therapeutics. The company leverages advancements in synthetic biology and deep learning to develop a proprietary non-antibody protein technology targeting GPCRs, including Chemokine Receptors, for applications in oncology, autoimmune diseases, and neuro-inflammatory disorders. As a pre-seed stage company, Aikium closed its latest funding round on November 15, 2024, and is led by CEO Venkatesh Mysore. Their innovative approach aims to revolutionize the field of protein therapeutics with cutting-edge research and development.

Recent Posts by Aikium

1-1 of 1